Cargando…

Patient perspectives on switching disease-modifying therapies in the NARCOMS registry

INTRODUCTION: The evolving landscape of disease-modifying therapies (DMTs) for multiple sclerosis raises important questions about why patients change DMTs. Physicians and patients could benefit from a better understanding of the reasons for switching therapy. PURPOSE: To investigate the reasons pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salter, Amber R, Marrie, Ruth Ann, Agashivala, Neetu, Belletti, Daniel A, Kim, Edward, Cutter, Gary R, Cofield, Stacey S, Tyry, Tuula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094626/ https://www.ncbi.nlm.nih.gov/pubmed/25045254 http://dx.doi.org/10.2147/PPA.S49903

Ejemplares similares

Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey
por: Rinker, John R, et al.
Publicado: (2015)

Sources of Cannabis Information and Medical Guidance for Neurologic Use: NARCOMS Survey of People Living With Multiple Sclerosis
por: Salter, Amber, et al.
Publicado: (2022)

Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study
por: Marrie, Ruth Ann, et al.
Publicado: (2014)

Preferred Sources of Health Information in Persons With Multiple Sclerosis: Degree of Trust and Information Sought
por: Marrie, Ruth Ann, et al.
Publicado: (2013)

Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2019)

The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry
por: Nickerson, Molly, et al.
Publicado: (2013)

A survey of risk tolerance to multiple sclerosis therapies
por: Fox, Robert J., et al.
Publicado: (2019)

National estimates of self-reported sitting time in adults with multiple sclerosis
por: Sasaki, JE, et al.
Publicado: (2018)

Uptake and Attitudes About Immunizations in People With Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Attitudes of people with multiple sclerosis toward brain donation
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

Physical and Mental Health–Related Quality of Life Trajectories Among People With Multiple Sclerosis
por: O'Mahony, Julia, et al.
Publicado: (2022)

Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey
por: Hadjimichael, Olympia, et al.
Publicado: (2008)

A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod
por: Salter, Amber, et al.
Publicado: (2021)

Severity and worsening of fatigue among individuals with multiple sclerosis
por: Salter, Amber, et al.
Publicado: (2023)

Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity
por: Raimundo, Karina, et al.
Publicado: (2013)

Switching to second line MS disease-modifying therapies is associated with decreased relapse rate
por: Marriott, James John, et al.
Publicado: (2023)

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age
por: Zhang, Yinan, et al.
Publicado: (2021)

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study
por: Agashivala, Neetu, et al.
Publicado: (2013)

Clinical trials in multiple sclerosis: milestones
por: Zhang, Yinan, et al.
Publicado: (2018)

Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis
por: Vasileiou, Eleni S., et al.
Publicado: (2022)

COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry
por: Newsome, Scott D., et al.
Publicado: (2021)

Evolution of clinical trials in multiple sclerosis
por: Zhang, Yinan, et al.
Publicado: (2019)

Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
por: Bergvall, Niklas, et al.
Publicado: (2014)

Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
por: Salter, Amber, et al.
Publicado: (2021)

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map
por: Khanani, Arshad M., et al.
Publicado: (2021)

Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
por: Zhang, Yinan, et al.
Publicado: (2020)

Treatment selection and experience in multiple sclerosis: survey of neurologists
por: Hanson, Kristin A, et al.
Publicado: (2014)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
por: Yu, Justin S, et al.
Publicado: (2021)

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
por: Calkwood, Jonathan, et al.
Publicado: (2014)

Etiology, effects and management of comorbidities in multiple sclerosis: recent advances
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Improving the efficiency of clinical trials in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

Regional Gray Matter Atrophy in Relapsing Remitting Multiple Sclerosis: Baseline Analysis of Multi-Center Data
por: Datta, Sushmita, et al.
Publicado: (2015)

The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hb0k830potjafq89tl17duq0or